Advertisement

The Evaluation of Beta Blocker and Calcium Antagonist Drugs

  • Joel Morganroth
  • E. Neil Moore

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 18)

Table of contents

  1. Front Matter
    Pages I-IX
  2. Joel Morganroth
    Pages 1-6
  3. D. C. Harrison
    Pages 183-188
  4. Arthur Hull Hayes Jr.
    Pages 217-230
  5. James A. Schoenberger
    Pages 231-232
  6. Lars Werkö
    Pages 233-245
  7. Stewart J. Ehrreich, Philip L. Dern, Mary Johnson
    Pages 247-260
  8. C. D. Furberg
    Pages 261-264
  9. Jerome Weinstein
    Pages 289-302
  10. Robert O’Rourke
    Pages 341-352
  11. Back Matter
    Pages 405-410

About this book

Introduction

With the beginning of the 1980's it was becoming increasingly evident that the lack of approval of new cardiovascular agents for use by clinicians in the United States for the treatment of cardiovascular disorders was becoming a problem. Patients requiring medical therapy for hypertension, angina pectoris, arrhythmias, congestive heart failure, and vasospastic disorders of the coronary arteries could receive in the United States only a small number of the drugs available to physicians in the rest of the world. In fact, as the 1980's began, there was only one available beta blocking agent released by The Food and Drug Administration; and even as of this writing, no oral calcium antagonist agent. This lag, in part, has been due to the confusion of proper and expeditious methods to define safety and efficacy of such agents so that the United States regulatory agency (Food and Drug Administration) could approve the use of such agents by clinicians. The vast number of new beta blocker and calcium antagonist agents being developed, as well as the long-term use abroad of many new drugs, has raised important questions as to how relative safety and efficacy of such agents can be determined to facilitate availability in the United States.

Keywords

angina pectoris arrhythmia coronary artery disease coronary heart disease drugs hypertension pharmacodynamics

Editors and affiliations

  • Joel Morganroth
    • 1
  • E. Neil Moore
    • 2
  1. 1.The Lankenau Medical Research CenterJefferson Medical College of The Thomas Jefferson UniversityPhiladelphiaUSA
  2. 2.School of Veterinary MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-009-7561-3
  • Copyright Information Springer Science+Business Media B.V. 1982
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-009-7563-7
  • Online ISBN 978-94-009-7561-3
  • Series Print ISSN 0166-9842
  • Buy this book on publisher's site